1. Academic Validation
  2. Celastrol inhibits the migration and invasion and enhances the anti-cancer effects of docetaxel in human triple-negative breast cancer cells

Celastrol inhibits the migration and invasion and enhances the anti-cancer effects of docetaxel in human triple-negative breast cancer cells

  • Med Oncol. 2022 Sep 7;39(12):189. doi: 10.1007/s12032-022-01792-y.
Zi Liu 1 Minghui Fan 1 Xiaojing Xuan 1 Chenlu Xia 1 Guozheng Huang 1 Liang Ma 2
Affiliations

Affiliations

  • 1 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, 59 Hudong Road, Ma'anshan, 243002, Anhui, People's Republic of China.
  • 2 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, 59 Hudong Road, Ma'anshan, 243002, Anhui, People's Republic of China. mal2014@ahut.edu.cn.
Abstract

The molecular mechanism of anti-metastatic effect of celastrol is not fully understood in breast Cancer cells. Herein, we investigated the activity and molecular mechanism of celastrol in triple-negative breast Cancer (TNBC) cells, which is a more aggressive subtype of breast Cancer. The results of wound healing assay and trans-well assay revealed that celastrol inhibited cell migration and invasion under sub-cytotoxic concentrations in MDA-MB-231 and MDA-MB-468 TNBC cells. Molecular data showed that the effect of celastrol on TNBC cells might be mediated via up-regulation of E-cadherin, a key protein involved in epithelial-mesenchymal transition (EMT). In addition, Hakai, an E3 Ligase responsible for E-cadherin complex ubiquitination and degradation, was down-regulated under celastrol treatment. Hakai partially contributed to celastrol-induced anti-invasive effect. In addition, celastrol and docetaxel could synergistically inhibit growth and metastasis of MDA-MB-231 cells. Our results showing anti-migratory/anti-invasive effects of celastrol and associated mechanisms provide new evidence for the development of celastrol as a potential anti-metastatic compound against highly aggressive breast Cancer, and celastrol in combination with docetaxel might potentially be used as a novel regimen for the treatment of TNBC.

Keywords

Celastrol; Docetaxel; E-cadherin; Hakai; Triple-negative breast cancer.

Figures
Products